Ultromics Develops World-first AI Technology Designed to Predict Heart Disease

Ultromics reports a revolutionary new medical device that can predict coronary artery disease – the number one cause of death globally – has been developed by a UK health-tech firm in a world first.

Ultromics notes heart disease is the number one cause of death in the UK and affects half of men and a third of women. It kills one in seven men and one in twelve women in the UK, striking every eight minutes.

The pioneering technology, called EchoGo Pro, is the first to successfully use artificial intelligence (AI) to make predictions about coronary heart disease (CAD) risk through ultrasound analysis – the primary imaging test to diagnose heart disease, with a staggering 60,000 Stress Echo scans performed in the UK each year.

EchoGo Pro has been developed by Ultromics, a spin-out company from the University of Oxford and is now CE marked allowing it to be used across the UK and the EU, with plans to submit for FDA clearance, so it can be used in the US by 2021.

Fast prognosis for medical teams

EchoGo Pro is able to deliver heart disease prognosis to hospital sites through its secure cloud system, built-in partnership with the NHS, based on thousands of past clinical exams. The system automatically analyses ultrasound images and applies artificial intelligence to identify disease, analyzing thousands of data points, compared to 5-6 indicators in traditional visual inspection. EchoGo Pro generates a report in minutes and sends a prognosis to the doctor treating the patient. Reducing misdiagnosis and enabling earlier prevention of heart disease

Ultromics co-founder and CEO, Ross Upton, said: “EchoGo Pro identifies the risk of heart disease, helping to detect early signs and enable preventative steps before a heart attack strikes, ultimately saving lives.

“The high level of precision and its speed of use means doctors, regardless of their level of experience or training, can make accurate recommendations to patients to help reduce misdiagnosis.”

Unfortunately, misdiagnosis of cardiovascular disease occurs in one in five patients due to a complex web of symptoms, circumstances, and comorbidities, which doesn’t make it easy for doctors to correctly identify conditions in traditional visual inspection. EchoGo Pro is able to identify these hard to spot features.

Ross added: “Misdiagnosis rates will be much lower and at-risk people can be treated quickly whilst those not at risk will be spared unnecessary tests, surgery, and other treatment.” The reduction in misdiagnoses can make a big difference to hospitals and healthcare providers, saving them money and medical resources. 

Optimizing care pathways and streamlining patient care

EchoGo Pro can mean valuable time savings for doctors and the healthcare system. The AI system streamlines hospital’s workflow, to help reduce the burden on doctors, freeing up their time so they can spend time with patients, and potentially treat more people.

Proven diagnostic performance

EchoGo Pro was trialed in the UK and US and achieved a diagnostic performance of over 90% (AUROC), halving the number of misdiagnoses compared to reports of routine clinical practice. The technology has been developed through its partnership in the EVAREST trial with the NHS, one of the largest ultrasound programs in the world, trained on tens of thousands of heart scans. The EVAREST validation trial continues to run in over 30 NHS hospitals and has recruited over 6000 patients.

Professor Paul Leeson, Head of the Oxford Cardiovascular Clinical Research Facility, who co-founded Ultromics with Mr. Upton, added: “The CE mark for EchoGo Pro is an important time in the battle against heart disease where real progress is being made to help improve patient outcomes and prevent heart disease. Leveraging AI technology means we can more accurately predict heart disease and optimize care pathways – to help make valuable cost and time savings for healthcare systems at this time when they are already stretched and in much need of support.”

In time, Ultromics hopes to develop versions of EchoGo Pro that can be deployed in handheld devices, and which can be used to improve heart function testing and analysis in remote areas of the world, or places with limited health infrastructure.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version